Genome-wide association and Mendelian randomization analysis prioritizes bioactive metabolites with putative causal effects on common diseases
Youwen Qin, Guillaume Méric, Tao Long, Jeramie D. Watrous, Stephen Burgess, Aki S. Havulinna, View ORCID ProfileScott C. Ritchie, Marta Brożyńska, Pekka Jousilahti, Markus Perola, Leo Lahti, Teemu Niiranen, Susan Cheng, Veikko Salomaa, Mohit Jain, Michael Inouye
doi: https://doi.org/10.1101/2020.08.01.20166413
Youwen Qin
1Cambridge Baker Systems Genomics Initiative, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia
2School of BioSciences, University of Melbourne, Melbourne, Victoria, Australia
Guillaume Méric
1Cambridge Baker Systems Genomics Initiative, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia
3Department of Infectious Diseases, Central Clinical School, Monash University, Melbourne, Victoria 3004, Australia
Tao Long
4Bioinformatics and Structural Biology Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA
5Departments of Medicine and Pharmacology, University of California, San Diego, CA, USA
Jeramie D. Watrous
5Departments of Medicine and Pharmacology, University of California, San Diego, CA, USA
Stephen Burgess
6MRC Biostatistics Unit, Institute of Public Health, University of Cambridge, Cambridge
7British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
Aki S. Havulinna
8Department of Public Health Solutions, Finnish Institute for Health and Welfare, Helsinki, Finland
Scott C. Ritchie
1Cambridge Baker Systems Genomics Initiative, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia
9Cambridge Baker Systems Genomics Initiative, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
10British Heart Foundation Centre of Research Excellence, University of Cambridge, Cambridge, UK
11National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge and Cambridge University Hospitals, Cambridge, UK
Marta Brożyńska
1Cambridge Baker Systems Genomics Initiative, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia
Pekka Jousilahti
8Department of Public Health Solutions, Finnish Institute for Health and Welfare, Helsinki, Finland
Markus Perola
8Department of Public Health Solutions, Finnish Institute for Health and Welfare, Helsinki, Finland
Leo Lahti
12Department of Future Technologies, University of Turku, Turku, Finland
Teemu Niiranen
8Department of Public Health Solutions, Finnish Institute for Health and Welfare, Helsinki, Finland
12Department of Future Technologies, University of Turku, Turku, Finland
Susan Cheng
13Division of Cardiology, Brigham and Women’s Hospital, Boston, USA
14Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
Veikko Salomaa
8Department of Public Health Solutions, Finnish Institute for Health and Welfare, Helsinki, Finland
Mohit Jain
5Departments of Medicine and Pharmacology, University of California, San Diego, CA, USA
Michael Inouye
1Cambridge Baker Systems Genomics Initiative, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia
2School of BioSciences, University of Melbourne, Melbourne, Victoria, Australia
7British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
9Cambridge Baker Systems Genomics Initiative, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
10British Heart Foundation Centre of Research Excellence, University of Cambridge, Cambridge, UK
11National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge and Cambridge University Hospitals, Cambridge, UK
15Health Data Research UK Cambridge, Wellcome Genome Campus and University of Cambridge, Cambridge, UK
16The Alan Turing Institute, London, UK
Data Availability
The data used in this study is available with an approved study proposal via the THL Biobank (FINRISK) and NIH dbGaP (Framingham Heart Study).
Posted August 04, 2020.
Genome-wide association and Mendelian randomization analysis prioritizes bioactive metabolites with putative causal effects on common diseases
Youwen Qin, Guillaume Méric, Tao Long, Jeramie D. Watrous, Stephen Burgess, Aki S. Havulinna, Scott C. Ritchie, Marta Brożyńska, Pekka Jousilahti, Markus Perola, Leo Lahti, Teemu Niiranen, Susan Cheng, Veikko Salomaa, Mohit Jain, Michael Inouye
medRxiv 2020.08.01.20166413; doi: https://doi.org/10.1101/2020.08.01.20166413
Genome-wide association and Mendelian randomization analysis prioritizes bioactive metabolites with putative causal effects on common diseases
Youwen Qin, Guillaume Méric, Tao Long, Jeramie D. Watrous, Stephen Burgess, Aki S. Havulinna, Scott C. Ritchie, Marta Brożyńska, Pekka Jousilahti, Markus Perola, Leo Lahti, Teemu Niiranen, Susan Cheng, Veikko Salomaa, Mohit Jain, Michael Inouye
medRxiv 2020.08.01.20166413; doi: https://doi.org/10.1101/2020.08.01.20166413
Subject Area
Subject Areas
- Addiction Medicine (386)
- Allergy and Immunology (701)
- Anesthesia (193)
- Cardiovascular Medicine (2859)
- Dermatology (244)
- Emergency Medicine (431)
- Epidemiology (12569)
- Forensic Medicine (10)
- Gastroenterology (807)
- Genetic and Genomic Medicine (4447)
- Geriatric Medicine (402)
- Health Economics (716)
- Health Informatics (2856)
- Health Policy (1050)
- Hematology (376)
- HIV/AIDS (893)
- Medical Education (415)
- Medical Ethics (114)
- Nephrology (464)
- Neurology (4201)
- Nursing (223)
- Nutrition (617)
- Oncology (2205)
- Ophthalmology (626)
- Orthopedics (254)
- Otolaryngology (319)
- Pain Medicine (269)
- Palliative Medicine (83)
- Pathology (488)
- Pediatrics (1172)
- Primary Care Research (483)
- Public and Global Health (6787)
- Radiology and Imaging (1494)
- Respiratory Medicine (902)
- Rheumatology (430)
- Sports Medicine (369)
- Surgery (473)
- Toxicology (57)
- Transplantation (202)
- Urology (174)